Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evasayil: placebo-controlled spesolimab trial in Netherton syndrome
jRCT2031220722Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Randomised, double-blind trial in Netherton syndrome (NS) comparing Spesolimab i.v. and s.c with Placebo i.v. and s.c (2 arms). Primary endpoint: IASI response at Week 16. Started Sep 2023; status: active, not recruiting.
02
Drugs
spesolimab
03
Conditions
Netherton syndrome (NS)
Beyond the preview
Go deeper on jRCT2031220722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220722.